Clinical trial
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
NCT00003109 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003109 |
|---|---|
| Title | Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors |
| Official title | Phase I Pharmacokinetic and Pharmacodynamic Trial of Irinotecan in Combination With Tomudex in Patients With Refractory Solid Malignancies |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride, raltitrexed |
| Enrollment | 39 |
| Start date | Dec 1, 1997 |
| Primary completion | Oct 1, 2000 |
| Completion | Jan 1, 2001 |
| First posted | Jul 8, 2004 |
| Last update posted | Apr 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: